BACKGROUND: Blood group A and B antigens are expressed only weakly on platelets (PLTs) of most individuals but are very strongly expressed on PLTs from approximately 1 percent of normal subjects (Type II high expressers). The implications of this trait for transfusion medicine are undefined. STUDY DESIGN AND METHODS: A family was studied in which two Group B infants were born with neonatal thrombocytopenia, whereas a third infant whose blood group was A(2) had a normal PLT count at birth. RESULTS: Serologic studies demonstrated a maternal antibody that reacted strongly with PLTs from the father and the two group B children in flow cytometry and with GPIIb/IIIa from their PLTs in solid-phase assays. No PLT-specific antibodies were detected in maternal serum sample, but it contained a high-titer immunoglobulin G antibody specific for blood group B. All PLT-reactive antibody in the mother's serum was removed by absorption with pooled, washed group A and B red cells (RBCs). Studies with monoclonal anti-B and measurement of serum B-glycosyltransferase activity showed that the father and both group B children were Type II high expressers of blood group B. CONCLUSIONS: The findings indicate that high-titer blood group antibodies acquired from the mother can cause thrombocytopenia in infants possessing the Type II high-expresser phenotype despite competition for antibody binding by blood group antigens expressed on RBCs and other tissues.
BACKGROUND: Blood group A and B antigens are expressed only weakly on platelets (PLTs) of most individuals but are very strongly expressed on PLTs from approximately 1 percent of normal subjects (Type II high expressers). The implications of this trait for transfusion medicine are undefined. STUDY DESIGN AND METHODS: A family was studied in which two Group B infants were born with neonatal thrombocytopenia, whereas a third infant whose blood group was A(2) had a normal PLT count at birth. RESULTS: Serologic studies demonstrated a maternal antibody that reacted strongly with PLTs from the father and the two group B children in flow cytometry and with GPIIb/IIIa from their PLTs in solid-phase assays. No PLT-specific antibodies were detected in maternal serum sample, but it contained a high-titer immunoglobulin G antibody specific for blood group B. All PLT-reactive antibody in the mother's serum was removed by absorption with pooled, washed group A and B red cells (RBCs). Studies with monoclonal anti-B and measurement of serum B-glycosyltransferase activity showed that the father and both group B children were Type II high expressers of blood group B. CONCLUSIONS: The findings indicate that high-titer blood group antibodies acquired from the mother can cause thrombocytopenia in infants possessing the Type II high-expresser phenotype despite competition for antibody binding by blood group antigens expressed on RBCs and other tissues.
Authors: Brian R Curtis; Saira Ali; Anne M Glazier; Douglas D Ebert; Timothy J Aitman; Richard H Aster Journal: Transfusion Date: 2002-09 Impact factor: 3.157
Authors: Julie A Peterson; Shannon M Pechauer; Maria L Gitter; Adam Kanack; Brian R Curtis; Jeff Reese; Vasudeva M Kamath; Janice G McFarland; Richard H Aster Journal: Transfusion Date: 2011-11-09 Impact factor: 3.157
Authors: Julie A Peterson; Maria Gitter; Daniel W Bougie; Shannon Pechauer; Kathleen A Hopp; Brad Pietz; Aniko Szabo; Brian R Curtis; Janice McFarland; Richard H Aster Journal: Transfusion Date: 2013-10-16 Impact factor: 3.157
Authors: Mia J Sullivan; Julie Peterson; Janice G McFarland; Daniel Bougie; Richard H Aster; Brian R Curtis Journal: Transfusion Date: 2014-12-15 Impact factor: 3.157
Authors: Julie A Peterson; Maria L Gitter; Adam Kanack; Brian Curtis; Janice McFarland; Daniel Bougie; Richard Aster Journal: Transfusion Date: 2009-10-10 Impact factor: 3.157
Authors: B M Sant'Anna Gomes; A C Estalote; M Palatnik; G Pimenta; B de B Pereira; E M Do Nascimento Journal: Transfus Med Date: 2010-10 Impact factor: 2.019
Authors: Maria Therese Ahlen; Anne Husebekk; Mette Kjær Killie; Jens Kjeldsen-Kragh; Martin L Olsson; Bjørn Skogen Journal: Clin Dev Immunol Date: 2011-11-02